| Interferon β-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C |
| |
| 引用本文： | Rinaldo Pellicano,Antonio Craxì,Piero Luigi Almasio,Mario Valenza,Giovanna Venezia,Alfredo Alberti,Silvia Boccato,Luigi Demelia,Orazio Sorbello,Antonino Picciotto,Francesco Torre,Gaetano Ideo,Carlo Cattaneo,Mara Berrutti,Mario Rizzetto.Interferon β-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C[J].世界胃肠病学杂志(英文版),2005(29). |
| |
| 作者姓名： | Rinaldo Pellicano Antonio Craxì Piero Luigi Almasio Mario Valenza Giovanna Venezia Alfredo Alberti Silvia Boccato Luigi Demelia Orazio Sorbello Antonino Picciotto Francesco Torre Gaetano Ideo Carlo Cattaneo Mara Berrutti Mario Rizzetto |
| |
| 作者单位： | U.O.A.D.U. Gastro-Hepatology S. Giovanni Battista (Molinette) Hospital Turin Italy，Venezia Department of Gastroenterology and Hepatology University of Palermo Italy，Venezia Department of Gastroenterology and Hepatology University of Palermo Italy，Venezia Department of Gastroenterology and Hepatology University of Palermo Italy，Venezia Department of Gastroenterology and Hepatology University of Palermo Italy，Department of Internal Medicine University of Padua Italy，Department of Internal Medicine University of Padua Italy，Institute of Clinical Medicine University of Cagliari Italy，Institute of Clinical Medicine University of Cagliari Italy，Department of Internal Medicine University of Genoa Italy，Department of Internal Medicine University of Genoa Italy，Department of Hepatology San Giuseppe Hospital Milan Italy，Department of Hepatology San Giuseppe Hospital Milan Italy，U.O.A.D.U. Gastro-Hepatology S. Giovanni Battista (Molinette) Hospital Turin Italy，U.O.A.D.U. Gastro-Hepatoiogy S. Giovanni Battista (Molinette) Hospital Turin Italy |
| |
| 基金项目： | Supported by an Unrestricted Grant From Industria Farmaceutica Serono S.p.A. (Rome, Italy). The Antiviral Drugs Employed in this Study were Also Made Available by Serono |
| |
| 摘 要： | AIM: To compare the efficacy and safety of recombinant human IFN β-1a alone or in combination with ribavirin in treatment-naive subjects with chronic hepatitis C. METHODS: Open, randomized trial was performed in 6 Italian tertiary centers: 102 of the 108 patients screened were randomized to receive 6 MIU of recombinant human IFN β-1a subcutaneously daily for 24 wk, alone (Group 1, n = 51) or in combination with ribavirin 1000 to 1200 mg/d (Group 2, n = 51). RESULTS: The end-of-treatment virologic response rate was 29.4% in Group 1 and 41.2% in Group 2 (nonsignificant). Twenty-four weeks after stopping therapy, sustained virologic response rate was 21.6% in Group 1 and 27.4% in Group 2 (non-significant). All subjects in Group 1 completed treatment, while two subjects in Group 2 stopped therapy due to treatment-related adverse events. CONCLUSION: Recombinant human IFN β-1a, alone or in combination with ribavirin, has an excellent safety profile and, may represent an alternative for chronic hepatitis C patients who are unable to tolerate pegylated α-interferon.
|
| 关 键 词： | Chronic hepatitis C IFN β-1a Ribavirin |
| 本文献已被 CNKI 等数据库收录！ |
|
